2015
DOI: 10.1586/17474086.2015.1036025
|View full text |Cite
|
Sign up to set email alerts
|

Emerging therapeutic targets in human acute myeloid leukemia (part 2) – bromodomain inhibition should be considered as a possible strategy for various patient subsets

Abstract: The recent advances in our understanding of leukemogenesis have clearly demonstrated that human acute myeloid leukemia is a heterogeneous malignancy, and several disease mechanisms should probably be regarded as possible therapeutic targets only for specific subsets of patients and not for acute myeloid leukemia in general. One promising strategy for epigenetic targeting is inhibition of the binding between bromodomain-containing transcription regulators and acetylated lysine residues on histones. This possibl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
3
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 99 publications
0
3
0
Order By: Relevance
“…Bromodomain-mediated interactions have key roles in transcriptional regulation and their dysfunction is implicated in a large number of diseases including cancer [183185], atherosclerosis [186] and diabetes [187]. …”
Section: Histone Acetyltransferase (Hat) Assaysmentioning
confidence: 99%
“…Bromodomain-mediated interactions have key roles in transcriptional regulation and their dysfunction is implicated in a large number of diseases including cancer [183185], atherosclerosis [186] and diabetes [187]. …”
Section: Histone Acetyltransferase (Hat) Assaysmentioning
confidence: 99%
“…The possibilities of combining CK2 inhibition with other antileukemic treatments are discussed in Section 8. Recent experimental studies of the effects of CK2 suggest that other combined strategies may also become relevant, e.g., combination with bromodomain inhibitors or other epigenetic strategies [126][127][128][129], targeting of AML cell metabolism [130,131], or targeting of CK2 regulators [132].…”
Section: General Discussion: the Need For Further Studies Of Silmitas...mentioning
confidence: 99%
“…For these patients leukemia-stabilizing treatment is possible, but the effect of such treatment varies between patients and many of them have a short survival of only a few months [ 17 , 18 , 19 , 20 ]. Furthermore, during the last decade, the biological heterogeneity with regard to leukemogenesis and chemosensitivity in AML has been extensively studied and many possible therapeutic strategies have been suggested based on experimental in vitro and in vivo studies [ 21 , 22 , 23 ]. However, even though four different approaches were recently approved for AML treatment, these strategies included more optimal use of well-known drugs or drugs that can be used only for subsets of patients [ 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ].…”
Section: Aml Heterogeneity and Prognostic Evaluationmentioning
confidence: 99%